Home » Topics » Infection, BioWorld Science

Infection, BioWorld Science
RSS

Novel antibacterial agents that inhibit bacterial two-component systems

Oct. 3, 1997

Wakunaga prepares acidic fluoroquinolone

Oct. 3, 1997

Triazole antifungal from Uriach heading for clinic

Oct. 2, 1997

SynPhar selects class C beta-lactamase inhibitor as development candidate

Oct. 2, 1997

T-3811: a new des-F(6)-quinolone from Toyama presented at ICAAC

Oct. 2, 1997

Wakunaga develops new oral fluoroquinolones

Oct. 2, 1997

Nyotran study results described at ICAAC

Oct. 2, 1997

BioChem Therapeutic discovers new anti-HCMV agents

Oct. 2, 1997

New polyene antifungal antibiotic developed at Ajinomoto

Oct. 2, 1997

ABT-606: a new orally active diester prodrug of H2G

Oct. 1, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.